In the cleanest controlled feeding study, semaglutide (the drug in Ozempic and Wegovy) cut daily food intake about 24%, roughly 725 fewer calories a day (about 3,036 kilojoules), in Blundell 2017.
That is the honest answer to how many calories Ozempic cuts: a figure measured in a lab, where people ate freely and researchers weighed exactly what they consumed, not a marketing estimate.
How does it happen? Semaglutide dials down appetite by acting on hunger-and-fullness signals in the brain, and like others in its class it slows how fast the stomach empties, so a meal feels filling for longer. In effect the medicine does a diet’s arithmetic for you, making less food feel like enough.
This article covers what the trials measured, the number in both calories and kilojoules, why your own figure will differ, why the effect shrinks over time, and where the medication fits. Set your expectations honestly first: some people respond much less than the average.
What the Feeding Studies Actually Measured
Quotes range from 200 to 900 calories because these studies do not measure the same thing. Some report a single meal. Others report a full day. Lining them up without checking the label is how the confusion starts.
Most of these figures come from free-eating studies, also called ad libitum studies. People get a set meal or a buffet, they are not told how much to eat, and researchers weigh what is left. That design measures appetite, not willpower, which is the point.
Here the single-meal versus whole-day split matters. Friedrichsen 2021, run at the higher Wegovy dose, measured one free-choice lunch and found it about 35% lower than placebo, roughly 225 fewer calories at that one meal. Blundell 2017 measured a full 24 hours of free eating and found intake about 24% lower, roughly 725 fewer calories across the whole day. That whole-day figure is the honest per-day number.
Tirzepatide adds another kind of measurement. In a 2025 trial published in Nature Medicine, people ate about 658 fewer calories at a single lunch by week 6, but that was measured against their own starting point, not a placebo group, and it covered one meal rather than a full day. So it cannot be lined up directly against the semaglutide daily figure.
The cleanest daily number stays the controlled 725 calories a day. Read each single-meal result as exactly that, one meal, not a stand-in for the whole day.
How Many Calories and Kilojoules the Cut Really Works Out To
Only one row below is a full day of eating; the other three are single meals. Here is every measured number in one place, in both calories and kilojoules, with the measurement spelled out.
| Study | Drug and dose | What was measured | Cut in calories | Cut in kilojoules |
|---|---|---|---|---|
| Blundell 2017 | Semaglutide 1.0mg (Ozempic dose) | Full 24-hour intake | ~725 fewer/day (~24%) | ~3,036 fewer/day |
| Friedrichsen 2021 | Semaglutide 2.4mg (Wegovy dose) | One free-choice lunch | ~225 fewer | ~940 fewer |
| Coskun/Martin 2025 | Tirzepatide | One lunch vs own baseline, wk 6 | ~658 fewer | ~2,753 fewer |
| Diabetes Care 2023 | Tirzepatide, 28 wks | One lunch vs placebo | ~310 fewer | ~1,297 fewer |
Note: only the Blundell 2017 row is a full-day figure. The other three are single-meal cuts, so they are naturally smaller than a whole day of eating.
The conversion is simple: 1 calorie equals 4.184 kilojoules. So about 500 calories is roughly 2,092 kilojoules, and the anchor 725 calories works out to about 3,036 kilojoules.
What does 725 calories look like in everyday food? Roughly a large fast-food combo, or a couple of slices of pizza, simply never eaten. That is the size of the daily gap the medicine opened in the lab.
One reality check before you bank on it. These are controlled-study figures, and real life varies enormously. The closest real-world estimate, Silver 2023, landed near 300 fewer calories a day, but with a spread of nearly 900 calories in either direction. Use 725 as an anchor to understand the effect, not a promise about your own week.
Why Your Own Calorie Cut Will Not Match the Study Number
If you are on the medicine and do not feel 725 calories lighter at the table, you are not doing it wrong. Three levers explain most of the gap between you and the trial average.
The first is dose. The appetite effect builds as you titrate up, meaning you start low and increase over weeks to limit side effects. Early low doses cut less, and the studies above used specific target doses, not the starting ones.
The second is which drug you take. Tirzepatide works on two gut-hormone signals at once (GIP and GLP-1), while semaglutide works on a single one (GLP-1), and directionally tirzepatide trends toward a bigger cut and bigger weight loss (up to about 20.9% in SURMOUNT-1 versus about 14.9% in STEP 1).
We need to be honest about the strength of that evidence, though. Head to head, the lunch gap was only about 64 calories and not statistically significant, meaning it could be down to chance, so “tirzepatide cuts far more” is a hint, not a settled fact.
The third is individual response. Roughly 10% to 17% of people, often cited as about 15%, lose less than 5% of their body weight on these drugs. For them the appetite effect, and the calorie cut behind it, is genuinely small, and that is biology rather than a personal failing.
Your number depends on:
- The dose you have actually reached
- Which drug you are taking
- Your own individual response
For how GLP-1s fit into the bigger weight-loss picture, see our guide to GLP-1 weight-loss medication.
Why the Deficit Shrinks the Longer You Take It
A plateau is not the drug failing; it is arithmetic catching up. Even if the medicine keeps cutting the same calories, the gap between what you eat and what you burn slowly closes on its own.
The mechanics are straightforward. Weight loss happens when your intake stays below your daily energy needs, sometimes called total daily energy expenditure or TDEE, roughly all the energy your body spends across 24 hours. Drop intake below that line and the body draws on stored fat to cover the difference.
Now add the twist. As you lose weight, a smaller body burns fewer calories at rest and in movement, and it gets a little more efficient, quietly economizing in a response known as adaptive thermogenesis. So the same 725-calorie food cut is no longer 725 below what you burn, because the burn side has dropped to meet it. The deficit narrows, and weight loss levels off.
One honest point about mechanism. GLP-1 drugs do not speed up your metabolism beyond the change that comes from carrying a smaller body; they work on the intake side, lowering how much you eat, not the burn side. The plateau, then, is expected math, not a sign of a broken drug.
The Calorie Deficit Is the Engine, and Where the Medication Fits
Weight loss runs on one engine: a calorie deficit, spending more energy than you take in. Everything about the number comes back to which side of that equation the medicine moves.
What makes these drugs different from willpower dieting is that they open the deficit pharmacologically, by making less food feel like enough, so success does not depend on white-knuckling hunger all day. That is the whole mechanism, and it is a real one.
Where does the medication fit? It is the appetite tool that opens the deficit. It does not choose what you eat, so protein and whole foods still matter, and it does not move your body for you, so activity still matters, both because they protect muscle and support the burn side of the balance. The drug widens the gap; your habits shape what happens inside it.
FAQs
How many calories does Ozempic cut per day?
About 725 fewer calories a day (roughly 3,036 kilojoules), around 24% of daily intake, in the Blundell 2017 feeding study using semaglutide at 1.0mg, the Ozempic-range dose. Researchers weighed the food while people ate freely in a lab. Your own cut in real life can be quite a bit smaller or larger.
Is the calorie cut the same on Wegovy?
Wegovy is the same drug, semaglutide, at a higher 2.4mg dose. In Friedrichsen 2021, one free-choice lunch ran about 35% lower, roughly 225 fewer calories at that single meal. A higher dose gives at least as large an appetite effect, so treat it as no smaller than the Ozempic-dose figure; no clean full-day 2.4mg number has been measured.
Does tirzepatide (Mounjaro or Zepbound) cut more calories?
Directionally yes, but not settled. Tirzepatide trends toward bigger weight loss (up to about 20.9% in SURMOUNT-1) and showed about 658 fewer calories at one lunch versus a person’s own baseline in the 2025 trial. Head to head with semaglutide 2.4mg, though, the single-meal gap was only about 64 calories and not statistically significant, so the edge looks real but unproven.
Will the calorie cut last, and what if I don’t lose weight?
The cut is real, but the deficit narrows over time: a smaller body needs fewer calories, so weight loss tends to plateau even on the drug. Roughly 10% to 17% of people lose less than 5% of their body weight, so being a lower responder is fairly common. If that is you, discuss options with your prescriber rather than assuming you failed.